Last reviewed · How we verify
NCT07041372: CARPET
Cerebral Atherosclerosis Research With Positron Emission Tomography
trial testing FDG-PET in Cerebral Infarction in 310 participants. Enrolling by invitation.
28 February 2029
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 310 |
| Start date | 22 June 2021 |
| Primary completion | 28 February 2029 |
| Estimated completion | 31 August 2029 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- FDG-PET — full drug profile →
Conditions studied
- Cerebral Infarction — all drugs for Cerebral Infarction →
Sponsor
Seoul National University Hospital
Who can join
19 and older, any sex, with Cerebral Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are: * Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors? * Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients. Participants will: * Undergo whole-body FDG PET once their neurological status has stabilized after stroke. * Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day. * Maintain regular clinic visits for up to 24 months following the index stroke
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07041372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of FDG-PET
Trials testing the same drug.
- NCT06797661 — Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. · NA · recruiting
- NCT06648317 — Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions · recruiting
- NCT06167603 — Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision · unknown
- NCT06019975 — FDG-PET in the Diagnosis of Autoimmune Encephalitis · recruiting
- NCT06833229 — Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or · recruiting
Other recruiting trials for Cerebral Infarction
Currently open trials in the same condition.
- NCT06757764 — The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis · Phase 4 · recruiting
- NCT07081568 — Research on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction · NA · recruiting
- NCT07018167 — Impact of Door-to-Needle Time on Stroke Outcomes at Gonesse Hospital · active not recruiting
- NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
- NCT06712004 — A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke · Phase 2 · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07041372 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07041372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing